Assetmark Inc. Sells 24,825 Shares of Bristol Myers Squibb Company $BMY

Key Points

• Assetmark Inc. reduced its Bristol Myers Squibb stake by 14.6% in the first quarter, selling 24,825 shares and leaving it with 144,837 shares valued at about $8.78 million.
• Wall Street remains cautious overall on BMY: analysts’ consensus rating is “Hold,” with a consensus price target of $61.25, despite several firms still assigning Buy ratings.
• Bristol Myers Squibb reported solid quarterly results and a dividend, beating EPS and revenue estimates, while also announcing a quarterly dividend of $0.63 per share, implying a 4.2% annual yield.

Assetmark Inc. cut its holdings in Bristol Myers Squibb Company (NYSE:BMY - Free Report) by 14.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 144,837 shares of the biopharmaceutical company's stock after selling 24,825 shares during the period. Assetmark Inc.'s holdings in Bristol Myers Squibb were worth $8,784,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Swiss RE Ltd. acquired a new stake in Bristol Myers Squibb during the fourth quarter worth approximately $25,000. Physician Wealth Advisors Inc. lifted its stake in Bristol Myers Squibb by 73.5% in the fourth quarter. Physician Wealth Advisors Inc. now owns 477 shares of the biopharmaceutical company's stock valued at $26,000 after buying an additional 202 shares during the period. Darwin Wealth Management LLC bought a new position in shares of Bristol Myers Squibb during the 2nd quarter worth approximately $25,000. Bayban acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $31,000. Finally, EQ Wealth Advisors LLC acquired a new stake in shares of Bristol Myers Squibb during the 4th quarter worth approximately $32,000. 76.41% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Weiss Ratings downgraded shares of Bristol Myers Squibb from a "hold (c+)" rating to a "hold (c)" rating in a research report on Thursday. Bank of America reduced their price target on shares of Bristol Myers Squibb from $67.00 to $66.00 and set a "buy" rating for the company in a report on Friday, July 10th. Cantor Fitzgerald reaffirmed a "neutral" rating and issued a $54.00 price target on shares of Bristol Myers Squibb in a research note on Monday, July 6th. Guggenheim reiterated a "buy" rating and set a $72.00 price objective on shares of Bristol Myers Squibb in a report on Wednesday, April 8th. Finally, UBS Group restated a "buy" rating on shares of Bristol Myers Squibb in a research note on Thursday, May 28th. Eight analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, Bristol Myers Squibb has a consensus rating of "Hold" and a consensus target price of $61.25.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $60.30 on Tuesday. Bristol Myers Squibb Company has a 1 year low of $42.52 and a 1 year high of $62.89. The company has a debt-to-equity ratio of 2.10, a current ratio of 1.42 and a quick ratio of 1.28. The firm has a market cap of $123.14 billion, a price-to-earnings ratio of 16.94, a PEG ratio of 0.17 and a beta of 0.23. The company has a fifty day moving average price of $57.11 and a 200-day moving average price of $57.85.

Bristol Myers Squibb (NYSE:BMY - Get Free Report) last released its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.58 earnings per share for the quarter, beating analysts' consensus estimates of $1.42 by $0.16. Bristol Myers Squibb had a net margin of 15.01% and a return on equity of 64.87%. The company had revenue of $11.49 billion for the quarter, compared to analyst estimates of $10.93 billion. During the same period last year, the firm earned $1.80 earnings per share. The firm's revenue was up 2.6% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.050-6.350 EPS. As a group, equities research analysts predict that Bristol Myers Squibb Company will post 6.34 EPS for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, August 3rd. Shareholders of record on Thursday, July 2nd will be given a dividend of $0.63 per share. The ex-dividend date of this dividend is Thursday, July 2nd. This represents a $2.52 annualized dividend and a dividend yield of 4.2%. Bristol Myers Squibb's dividend payout ratio (DPR) is currently 70.79%.

More Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers Squibb expanded its NVIDIA partnership and plans to deploy a DGX SuperPOD based on Vera Rubin systems, which the company says will become the most powerful AI factory in life sciences and should enhance drug discovery and development efficiency. Bristol Myers Expands NVIDIA Partnership to Build Top Life Sciences AI Supercomputer
• Positive Sentiment: The company also said it will be the first life sciences firm to buy Nvidia’s latest DGX SuperPOD system, signaling an aggressive investment in AI infrastructure that could strengthen Bristol Myers’ competitive position in future drug research. Bristol Myers buys Nvidia's latest AI computing system for drug research
• Neutral Sentiment: A Reuters report repeated the AI-infrastructure news, reinforcing the strategic nature of the announcement but adding no materially new information for investors. Bristol Myers buys Nvidia's latest AI computing system for drug research
• Neutral Sentiment: Bristol Myers was mentioned in a broader article about cancer-drug competition and next-generation therapies, but the piece mainly discussed the market landscape rather than any company-specific development. Merck’s Keytruda Faces a Patent Cliff. These New Cancer Drugs Could Take Over.
• Negative Sentiment: Healthcare stocks fell late Monday afternoon, which may be creating a modest drag on BMY and offsetting some of the optimism from the NVIDIA partnership news. Sector Update: Healthcare Stocks Fall Late Afternoon

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company's core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS's marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol Myers Squibb Company (NYSE:BMY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.